Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum

Journal of Immunological Methods

Volumn 376, Issue 1-2, 2012, Pages 32-45

  Chen, Xinyi C ^a   Zhou, Lei ^a   Gupta, Shalini ^a   Civoli, Francesca ^a  

^a AMGEN INC   (United States)

Author keywords

Design of experiments; Fractional factorial design; Neutralizing antibodies; Response surface model

Indexed keywords

CONATUMUMAB; DEATH RECEPTOR 5; NEUTRALIZING ANTIBODY;

ACCURACY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; APOPTOSIS; ARTICLE; CELL AGING; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL SPECIFICITY; CONTROLLED STUDY; CROSS LINKING; DESIGN OF EXPERIMENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LIFE CYCLE; PRIORITY JOURNAL; STUDY DESIGN; TUMOR CELL; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; CASPASES; CELL LINE, TUMOR; HUMANS; LIMIT OF DETECTION; MODELS, STATISTICAL; SENSITIVITY AND SPECIFICITY;

EID: 84856539081     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.11.004     Document Type: Article

References (18)

1. Altan S., Bergum J., Pfahler L., Senderak E., Sethuraman S., Vukovinsky K. Statistical considerations in design space development. Pharm. Technol. 2010, 34:66.
2. Altekar M., Homon C., Kashem M., Mason S., Nelson R., Patnaude L., Yingling J., Taylor P. Assay optimization: a statistical design of experiments approach. Clin. Lab. Med. 2007, 27:139.
3. Anderson M., Whitcomb P. DOE Simplified: Practical Tools for Effective Experimentation 2007, Productivity Press, New York.
4. Antony J. Design of Experiments for Engineers and Scientists 2003, Elsevier, Oxford.
5. Box G., Cox D. An analysis of transformations. J. R. Stat. Soc. B 1964, 26:211.
6. Dejaegher B., Heyden Y. Ruggedness and robustness testing. J. Chromatogr. A 2007, 1158:138.
7. Duiker E., Mom C., de Jong S., Willemse P., Gietema J., van der Zee A., de Vries E. The clinical trail of TRAIL. Eur. J. Cancer 2006, 42:2233.
8. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35:495.
9. Gupta S., Indelicato S., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A., Richards S., Rup B., Shores E., Swanson S., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1.
10. Huang J., Kaul G., Cai C., Chatlapalli R., Hernandez-Abad P., Ghosh K., Nagi A. Quality by design case study: an integrated multivariate approach to drug product and process development. Int. J. Pharm. 2009, 382:23.
11. Joelsson D., Moravec P., Troutman M., Pigeon J., DePhillips P. Optimizing ELISAs for precision and robustness using laboratory automation and statistical design of experiments. J. Immunol. Methods 2008, 337:35.
12. Kaplan-Lefko P., Graves J., Zoog S., Pan Y., Wall J., Branstetter D., Moriguchi J., Coxon A., Huard J., Xu R., Peach M., Juan G., Kaufman S., Chen Q., Bianchi A., Kordich J., Ma M., Foltz I., Gliniak B. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol. Ther. 2010, 9:1.
13. Ray C., Patel V., Shih J., Macaraeg C., Wu Y., Thway T., Ma M., Lee J., DeSilva B. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. J. Pharm. Biomed. Anal. 2009, 49:311.
14. Rowinsky E. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 2005, 23:9394.
15. Shankar G., Devanarayan V., Amaravadi L., Barrett Y., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267.
16. Shapiro S., Wilk M. An analysis of variance test for normality (complete samples). Biometrika 1965, 52:591.
17. Sittampalam G., Smith W., Miyakawa T., Smith D., McMorris C. Application of experimental design techniques to optimize a competitive ELISA. J. Immunol. Methods 1996, 190:151.
18. U.S.Department of Health and Human Services, Food and Drug Administration Guidance for industry: assay development for immunogenicity testing of therapeutic proteins http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf.